Literature DB >> 22361432

Deep venous thrombosis in children with musculoskeletal infections: the clinical evidence.

Elpis Mantadakis1, Eleni Plessa, Evridiki K Vouloumanou, Lambros Michailidis, Athanassios Chatzimichael, Matthew E Falagas.   

Abstract

BACKGROUND: Clinical manifestations of deep venous thrombosis (DVT) tend to overlap with those of deep-seated musculoskeletal infections (MSIs). Consequently, the incidence of DVT as a complication of MSI may be underestimated. The objective of this study was to evaluate the incidence, clinical features, and outcomes of MSI-related DVT in children.
METHODS: We systematically reviewed relevant studies retrieved from PubMed and Scopus databases.
RESULTS: Overall, 93 children with MSIs who developed DVT were identified from 28 retrospective studies. The majority were boys. Osteomyelitis was the most frequent MSI (69/74, 93%). Staphylococcus aureus was the predominant pathogen (83/93, 89%); 61% of these isolates were methicillin-resistant S. aureus (MRSA). Pulmonary involvement, presumably due to septic emboli, was observed in 65% of the included children. Four children died due to multiple organ failure and two due to respiratory distress. In two of the three studies providing comparative data, MRSA infections were observed significantly more frequently in children who developed DVT compared to those who did not. Yet, the respective differences observed for methicillin-susceptible S. aureus (MSSA) infections were non-significant in these three studies.
CONCLUSIONS: Despite the inclusion of many case reports and the retrospective design of the evaluated studies, our findings suggest that boys seem to be more frequently affected by MSIs complicated by DVT. Moreover, MRSA seems to be more frequently associated with DVT compared to MSSA. Pulmonary involvement appears to be a frequent complication. Prospective studies are needed in order to further clarify this issue. Copyright Â
© 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22361432     DOI: 10.1016/j.ijid.2011.12.012

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  A Clinical Prediction Algorithm to Stratify Pediatric Musculoskeletal Infection by Severity.

Authors:  Michael A Benvenuti; Thomas J An; Megan E Mignemi; Jeffrey E Martus; Gregory A Mencio; Stephen A Lovejoy; Jonathan G Schoenecker; Derek J Williams
Journal:  J Pediatr Orthop       Date:  2019-03       Impact factor: 2.324

2.  [Acute haematogenous osteomyelitis in children : Diagnostic algorithm and treatment strategies].

Authors:  M Willegger; A Kolb; R Windhager; C Chiari
Journal:  Orthopade       Date:  2017-06       Impact factor: 1.087

Review 3.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 4.  Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.

Authors:  K Z Vardakas; I Kontopidis; I D Gkegkes; P I Rafailidis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-20       Impact factor: 3.267

Review 5.  Venous thromboembolism in critically ill children.

Authors:  Lee A Polikoff; E Vincent S Faustino
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

6.  Panton-Valentine Leukocidin associated with S. aureus osteomyelitis activates platelets via neutrophil secretion products.

Authors:  Silke Niemann; Anne Bertling; Martin F Brodde; Anke C Fender; Hélène Van de Vyver; Muzaffar Hussain; Dirk Holzinger; Dirk Reinhardt; Georg Peters; Christine Heilmann; Bettina Löffler; Beate E Kehrel
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.